{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:24:12Z","timestamp":1791894252635,"version":"4.3.4"},"reference-count":33,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,10]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The CREBBP lysine acetyltransferase (KAT) is frequently mutated in follicular lymphoma and diffuse large B-cell lymphoma and has been studied using gene knockout in murine and human cells. However, most CREBBP mutations encode amino acid substitutions within the catalytic KAT domain (CREBBP KAT-PM) that retain an inactive protein and have not been extensively characterized. Using CRISPR gene editing and extensive epigenomic characterization of lymphoma cell lines, we found that CREBBP KAT-PM lead to unloading of CREBBP from chromatin, loss of enhancer acetylation, and prevention of EP300 compensation. These enhancers were enriched for those that are dynamically loaded by CREBBP in the normal centroblast-to-centrocyte transition in the germinal center, including enhancers activated in response to CD40 signaling, leading to blunted molecular response to CD40 ligand in lymphoma cells. We provide evidence that CREBBP KAT-PM inhibits EP300 function by binding limiting quantities nuclear transcription factor (TF), thereby preventing its compensatory activity. This effect can be experimentally overcome by expressing saturating quantities of TF or biologically attenuated by strong stimulation of CD40 signaling that increases nuclear TF abundance. Importantly, epigenetic responses to CD40 signaling can be induced by enforcing CD4 T-cell engagement using a bispecific antibody, leading to CD40-dependent restoration of antigen presentation machinery in CREBBP KAT-PM cells and cell death. Therefore, we provide a mechanistic basis for enhancer deregulation by CREBBP KAT-PM and highlight enforced CD4 T-cell engagement as a potential approach for overcoming these effects.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024026664","type":"journal-article","created":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T17:05:26Z","timestamp":1742144726000},"page":"191-205","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Blunted CD40-responsive enhancer activation in <i>CREBBP<\/i>-mutant lymphomas can be restored by enforced CD4 T-cell engagement"],"prefix":"10.1182","volume":"146","author":[{"given":"Haopeng","family":"Yang","sequence":"first","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"2Unit\u00e9 de Biologie Fonctionnelle et Adaptative, Universit\u00e9 Paris Cit\u00e9, Centre National de la Recherche Scientifique, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vida","family":"Ravanmehr","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiling","family":"Cui","sequence":"additional","affiliation":[{"name":"2Unit\u00e9 de Biologie Fonctionnelle et Adaptative, Universit\u00e9 Paris Cit\u00e9, Centre National de la Recherche Scientifique, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Bowman","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"3The University of Texas MD Anderson Cancer Center, UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruidong","family":"Chen","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared M.","family":"Henderson","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9021-4970","authenticated-orcid":false,"given":"Shyanne","family":"Lockman","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estela","family":"Rojas","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Wilson","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2223-2121","authenticated-orcid":false,"given":"Sydney","family":"Parsons","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5305-7495","authenticated-orcid":false,"given":"Ariel","family":"Mechaly","sequence":"additional","affiliation":[{"name":"4Plateforme de Cristallographie-C2RT, Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, Centre National de la Recherche Scientifique, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9292-5283","authenticated-orcid":false,"given":"Leslie","family":"Regad","sequence":"additional","affiliation":[{"name":"2Unit\u00e9 de Biologie Fonctionnelle et Adaptative, Universit\u00e9 Paris Cit\u00e9, Centre National de la Recherche Scientifique, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1196-1635","authenticated-orcid":false,"given":"Ahmed","family":"Haouz","sequence":"additional","affiliation":[{"name":"4Plateforme de Cristallographie-C2RT, Institut Pasteur, Universit\u00e9 Paris Cit\u00e9, Centre National de la Recherche Scientifique, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9524-3990","authenticated-orcid":false,"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-4914","authenticated-orcid":false,"given":"Sattva","family":"Neelapu","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6071-8610","authenticated-orcid":false,"given":"Loretta","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9197-2523","authenticated-orcid":false,"given":"R. Eric","family":"Davis","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Deng","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-4767","authenticated-orcid":false,"given":"Fernando","family":"Rodrigues-Lima","sequence":"additional","affiliation":[{"name":"2Unit\u00e9 de Biologie Fonctionnelle et Adaptative, Universit\u00e9 Paris Cit\u00e9, Centre National de la Recherche Scientifique, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6309-9472","authenticated-orcid":false,"given":"Michael R.","family":"Green","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"3The University of Texas MD Anderson Cancer Center, UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX"},{"name":"5Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2025071011263494200_bib2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/blood-2017-08-737361","article-title":"Chromatin modifying gene mutations in follicular lymphoma","volume":"131","author":"Green","year":"2018","journal-title":"Blood"},{"issue":"7337","key":"2025071011263494200_bib3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"issue":"7337","key":"2025071011263494200_bib4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature09727","article-title":"CREBBP mutations in relapsed acute lymphoblastic leukaemia","volume":"471","author":"Mullighan","year":"2011","journal-title":"Nature"},{"issue":"3","key":"2025071011263494200_bib5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.immuni.2019.08.006","article-title":"(2019). Unique and shared epigenetic programs of the CREBBP and EP300 acetyltransferases in germinal center B cells reveal targetable dependencies in lymphoma","volume":"51","author":"Meyer","year":"2019","journal-title":"Immunity"},{"issue":"3","key":"2025071011263494200_bib6","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2159-8290.CD-19-0116","article-title":"Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma","volume":"10","author":"Mondello","year":"2020","journal-title":"Cancer Discov"},{"issue":"10","key":"2025071011263494200_bib7","doi-asserted-by":"crossref","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","article-title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation","volume":"112","author":"Green","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2025071011263494200_bib8","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3324\/haematol.2020.274258","article-title":"Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma","volume":"107","author":"Ma","year":"2022","journal-title":"Haematologica"},{"issue":"12","key":"2025071011263494200_bib9","doi-asserted-by":"crossref","first-page":"e1002197","DOI":"10.1371\/journal.pmed.1002197","article-title":"Histological transformation and progression in follicular lymphoma: a clonal evolution study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS Med"},{"issue":"8","key":"2025071011263494200_bib11","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2025071011263494200_bib10","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2016-07-729954","article-title":"Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma","volume":"129","author":"Krysiak","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2025071011263494200_bib12","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1182\/blood-2013-05-500595","article-title":"Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma","volume":"123","author":"Bouska","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2025071011263494200_bib13","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"issue":"5","key":"2025071011263494200_bib14","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes [published correction appears in Nat Med. 2018;24(8):1292]","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"15","key":"2025071011263494200_bib15","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"2025071011263494200_bib16","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2025071011263494200_bib17","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/leu.2017.251","article-title":"Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets","volume":"32","author":"Karube","year":"2018","journal-title":"Leukemia"},{"key":"2025071011263494200_bib20","doi-asserted-by":"crossref","first-page":"e21856","DOI":"10.7554\/eLife.21856","article-title":"An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites","volume":"6","author":"Skene","year":"2017","journal-title":"Elife"},{"issue":"1","key":"2025071011263494200_bib21","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.molcel.2015.11.003","article-title":"A multiplexed system for quantitative comparisons of chromatin landscapes","volume":"61","author":"van Galen","year":"2016","journal-title":"Mol Cell"},{"issue":"45","key":"2025071011263494200_bib22","doi-asserted-by":"crossref","first-page":"32091","DOI":"10.1074\/jbc.274.45.32091","article-title":"The nuclear factor-kappaB engages CBP\/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter","volume":"274","author":"Vanden Berghe","year":"2017","journal-title":"J Biol Chem"},{"issue":"9","key":"2025071011263494200_bib23","doi-asserted-by":"crossref","first-page":"e1001647","DOI":"10.1371\/journal.pbio.1001647","article-title":"Analysis of the RelA:CBP\/p300 interaction reveals its involvement in NF-\u03baB-driven transcription","volume":"11","author":"Mukherjee","year":"2013","journal-title":"PLoS Biol"},{"key":"2025071011263494200_bib24","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.3389\/fimmu.2018.03086","article-title":"The molecular basis of viral inhibition of IRF- and STAT-dependent immune responses","volume":"9","author":"Chiang","year":"2018","journal-title":"Front Immunol"},{"issue":"9","key":"2025071011263494200_bib25","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/nsmb.2642","article-title":"Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation","volume":"20","author":"Delvecchio","year":"2013","journal-title":"Nat Struct Mol Biol"},{"issue":"8","key":"2025071011263494200_bib26","first-page":"1922","article-title":"BCL10 mutations define distinct dependencies guiding precision therapy for DLBCL","volume":"12","author":"Xia","year":"2022","journal-title":"Cancer Discov"},{"issue":"2","key":"2025071011263494200_bib27","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1042\/BST20160400","article-title":"Bio-Zombie: the rise of pseudoenzymes in biology","volume":"45","author":"Murphy","year":"2017","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"2025071011263494200_bib28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12915-016-0322-x","article-title":"The evolving world of pseudoenzymes: proteins, prejudice and zombies","volume":"14","author":"Eyers","year":"2016","journal-title":"BMC Biol"},{"key":"2025071011263494200_bib30","doi-asserted-by":"crossref","first-page":"e10483","DOI":"10.7554\/eLife.10483","article-title":"Bromodomain inhibition of the transcriptional coactivators CBP\/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma. [published correction appears in Elife. 2016:5:e19432]","volume":"5","author":"Conery","year":"2016","journal-title":"Elife"},{"key":"2025071011263494200_bib31","article-title":"Unveiling IRF4-steered regulation of context-dependent effector programs in Th17 and Treg cells","author":"Gabele","year":"15  2023","journal-title":"bioRxiv"},{"issue":"5","key":"2025071011263494200_bib32","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1158\/1078-0432.CCR-12-2064","article-title":"Agonistic CD40 antibodies and cancer therapy","volume":"19","author":"Vonderheide","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2025071011263494200_bib33","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"issue":"19","key":"2025071011263494200_bib18","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2016-08-733469","article-title":"Crebbp loss cooperates with Bcl2 over-expression to promote lymphoma in mice","volume":"129","author":"Garc\u00eda-Ram\u00edrez","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2025071011263494200_bib19","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1158\/2159-8290.CD-16-1417","article-title":"The Crebbp acetyltransferase is a haploinsufficient tumor suppressor in B cell lymphoma","volume":"7","author":"Zhang","year":"2017","journal-title":"Cancer Discov"},{"issue":"1","key":"2025071011263494200_bib34","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/2159-8290.CD-16-0975","article-title":"CREBBP inactivation promotes the development of HDAC3-dependent lymphomas","volume":"7","author":"Jiang","year":"2017","journal-title":"Cancer Discov"},{"issue":"1","key":"2025071011263494200_bib36","doi-asserted-by":"crossref","first-page":"12742","DOI":"10.1038\/s41598-023-39608-2","article-title":"Mutational landscape of cancer-driver genes across human cancers","volume":"13","author":"Sinkala","year":"2023","journal-title":"Sci Rep"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/2\/191\/2402489\/blood_bld-2024-026664-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/2\/191\/2402489\/blood_bld-2024-026664-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T15:26:40Z","timestamp":1752161200000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/2\/191\/536102\/Blunted-CD40-responsive-enhancer-activation-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024026664","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,10]]},"published":{"date-parts":[[2025,7,10]]}}}